Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats

BACKGROUND: Osimertinib, as third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment approved to treat advanced T790M mutation-positive tumors. Triazole antifungals are therapeutic drugs for cancer patients to reduce the risk of opportunisti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Yutao, Song, Feifeng, Cheng, Mengting, Hu, Ying, Chai, Yitao, Hu, Qing, Wang, Qiyue, Zhou, Hongying, Bao, Meihua, Gu, Jinping, Zhang, Yiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2023
Materias:
Biochemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423561/
https://www.ncbi.nlm.nih.gov/pubmed/37581117
http://dx.doi.org/10.7717/peerj.15844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423561/
https://www.ncbi.nlm.nih.gov/pubmed/37581117
http://dx.doi.org/10.7717/peerj.15844

Ejemplares similares